Assembly Biosciences presents new data on ABI-6250

Assembly Biosciences announced new data for ABI-6250, the company’s orally bioavailable, small molecule hepatitis D virus entry inhibitor candidate, featured in a poster presentation at the European Association for the Study of the Liver, EASL, Congress, taking place June 5-8, 2024, in Milan, Italy. The poster presentation “Preclinical profiling of ABI-6250, a novel orally bioavailable small-molecule therapeutic candidate for the treatment of chronic hepatitis D” will highlight preclinical data that support the advancement of ABI-6250 into Phase 1 clinical studies. Results from preclinical evaluation included in this presentation demonstrate that ABI-6250 can effectively inhibit, at low nanomolar levels, HDV infection of the most prevalent genotypes in HepG2-NTCP cells. ABI-6250 also effectively inhibited NTCP-mediated bile acid uptake and demonstrated selectivity for the NTCP bile transporter versus other transporters in vitro.